Current Headlines

  1. Curie-Cancer, GamaMabs Renew Collaboration For Biologic Ovarian Cancer Drug
    12/19/2014

    GamaMabs Pharma, a biotech specializing in the development of biologic cancer drugs, announced the extension of their collaboration with Curie-Cancer, a leading academic research institute.

  2. Zafgen Starts Phase 2 Trial Of Beloranib In Severe Obesity
    12/18/2014

    Zafgen, a company focusing on obesity and complex metabolic disorders, has begun a Phase 2 trial of beloranib.

  3. CMC Biologics, OncoSynergy To Co-Develop Ebola Drug Lead
    12/18/2014

    CMC Biologics announced that it has entered into agreement with OncoSynergy for accelerated process development and Good Manufacturing Practices (GMP) production for the investigational drug OS2966 targeting the Ebola virus.

  4. AstraZeneca Posts Positive Data For Faslodex In Breast Cancer
    12/18/2014

    AstraZeneca presented new data for its investigational drug Faslodex (fulvestrant) as treatment for hormone-receptor positive breast cancer compared to Arimidex (anastrozole) at the recent 2014 San Antonio Breast Cancer Symposium (SABCS).

  5. Alkermes Begins Phase 1 Trial For Schizophrenia Drug
    12/18/2014

    Alkermes announced that it has started a Phase 1 study to investigate extended dosing intervals of aripiprazole lauroxil as treatment for schizophrenia.

  6. Pfizer To Develop GHD Drug With OPKO Health
    12/18/2014

    Pfizer announced it has partnered with Miami-based OPKO Health to develop the latter's long-acting hGH-CTP as treatment for growth hormone deficiency (GHD) syndrome in both adults and children, as well as for growth failure in children born small for gestational age (SGA) who fall short of catch-up growth standard by 2 years old.

  7. EMA Backs MorphoSys' Orphan Application For MOR208 In DLCBL
    12/18/2014

    MorphoSys, a company specializing in developing therapeutic antibodies, announced that it has received the positive opinion of the European Medicines Agency for the Orphan Medicinal Product Designation application of its drug MOR208 as a treatment for diffuse large B-cell lymphoma (DLBCL).

  8. U.K., U.S. Collaboration Seeks To Repurpose Drugs As Neurological Treatments
    12/18/2014

    U.S. non-profit, Alzheimer’s Drug Discovery Foundation (ADDFF) and the Alzheimer’s Society U.K. (ASUK) announced they would be funding two separate clinical trials to establish alternate proof of concept and potentially repurpose two pipeline medications indicated for separate illnesses. One study will test the efficacy of an erectile dysfunction (ED) medication against vascular dementia, and the other will test a diabetes medication as an Alzheimer’s treatment.

  9. Carlina, Atlangram Partner On Osteoarticular Infectious Diseases Antibiotics
    12/17/2014

    Carlina Technologies has partnered with Atlangram to develop innovative antibiotics for osteoarticular infectious diseases.

  10. AMR Superbugs Could “Cast Medicine Back To The Dark Ages,” Says Study
    12/17/2014

    A new study commissioned by the British government estimates that by 2050, antimicrobial- resistant (AMR) disease could take 10 million lives per year and rack up a global cost of over $100 trillion. The figures reinforce the importance of investment in new, effective AMR drugs, Reuters reports.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.